2018 disclosure of interest information · soren erik pedersen, md - chair helen k. reddel, mbbs,...

2018 DISCLOSURE OF INTEREST INFORMATION

GINA BOARD OF DIRECTORS

Louis-Philippe Boulet MD - Chair

Eric D. Bateman, MD

Guy Brusselle, MD, PhD, FERS

Alvaro A. Cruz, MD

Mark FitzGerald, MD

Hiromasa Inoue, MD

Mark L. Levy, MD

Jiangtao Lin, MD

Soren Erik Pedersen, MD - Chair

Helen K. Reddel, MBBS, PhD

Arzu Yorgancioglu, MD

Helen K. Reddel, MBBS, PhD - Chair

Len Bacharier, MD

Eric D. Bateman, MD

Louis-Philippe Boulet MD

Guy Brusselle, MD, PhD, FERS

Dr. Roland Buhl

Mark FitzGerald, MD

Louise Fleming, MD

Hiromasa Inoue, MD

Jerry A. Krishnan, MD, PhD

Soren Erik Pedersen, MD

Aziz Sheikh, MD

Dr Fanny Wai-san Ko

GINA SCIENCE COMMITTEE

GLOBAL INIT IATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTERESTJanuary 1, 2018 - December 31, 2018

BackgroundThe Global Initiative for Asthma (GINA) program is a collaboration between the scientific community and the private sector. The major objectives are: (1) to increase awareness of asthma among health professionals, health authorities, and the general public; (2) improve diagnosis, management, and prevention; and (3) stimulate research. These objectives are being met through preparation of scientific reports on asthma, dissemination and adoption of recommendations in these reports, and promotion of international collaboration on asthma research.

The purpose of this document is to safeguard the interests of all GINA collaborators by an open disclosure of interests.

GINA StructureAt present, the GINA program is conducted through a GINA Board of Directors that meets annually (usually in January), a Scientific Committee and a Dissemination Committee. Each Committee will have an active role in reviewing and recommending content for GINA documents and all members will be asked to complete this form.

Annual Declaration of InterestsThe following declarations are requested by GINA. Please complete the company name select in thecorresponding box whether you have financial relationships (received grants, personal fees, shares, non-financial support, other). Please include all companies in the bio-medical arena, as well as telehealth/technology, and tobacco entities. This form will be posted on the GINA website after completion.

Definitions:

1. Grants: refers to any grant paid to your organization.

2. Personal Fees: refers to honorarium, consultation fees, etc for lectures, advisory committees or consultancy services either intermittent or regular, from which a GINA member benefits personally. This includes ongoing attendance at advisory board meetings but would not normally include a situation where an individual is paid for a specific item or for attending or speaking at an occasional meeting.

3. Shares: refers to any shares in asthma-related commercial organizations, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GINA member or family members (spouse/children). The company is to be listed, not the number of shares.

4. Non-Financial Support: In-kind assistance.

The private sector should not in any way be involved in any aspect of developing documents, includingcollecting, reviewing or accessing the literature or determining the content. Once documents have beenproduced asthma-related commercial organizations can be involved in their dissemination and audit, including support for publications.

GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST Name: Louis-Philippe BOULET Member of: Chair of the Board of Directors of the GINA Chair of the Global Initiative for Asthma (GINA Guidelines) Dissemination and Implementation Committee Are there any relevant financial interests to disclose? Here are some potential COI for 2018

Name of Entity Grant? Personal Fee?

Non-Financial Support? Other? Comments:

AstraZeneca x Research grants for participation to multicentre

Boston Scientific x Research grants for participation to multicentre

GlaxoSmithKline x Research grants for participation to multicentre

Hoffman La Roche x

Research grants for participation to multicentre

Novartis x Research grants for participation to multicentre

Ono Pharma x Research grants for participation to multicentre

Sanofi Takeda x Research grants for participation to multicentre

AstraZeneca x Consulting and advisory boards

Novartis x Consulting and advisory boards

Methapharm x Consulting and advisory boards

AstraZeneca x Conference fees

GlaxoSmithKline x Conference fees

Merck Frosst x Conference fees

Novartis x Conference fees

Novartis x Support for participation in conferences and meetings

Takeda x Support for participation in conferences and meetings

AstraZeneca x

Nonprofit grants for production of educational materials

Boehringer-Ingelheim x


GlaxoSmithKline x


Merck Frosst x


Novartis x


GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST Name: Professor Eric D Bateman

Member of: GINA Board of Directors, GINA Science Committee Are there any relevant financial interests to disclose? Yes; see below



Novartis yes Advisory board Sanofi-Aventis yes Advisory board

ALK yes Consultancy & Lecture fee

ICON yes

Study oversight steering committee

Regeneron yes Advisory board

AstraZeneca yes Advisory board & lecture fees

Boehringer Ingelheim yes Lecture fee

GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST Name: Brusselle Guy

Member of: GINA Board of Directors, GINA Science Committee Are there any relevant financial interests to disclose? Yes



AstraZeneca Yes Advisory boards and lecture fees

Chiesi Yes Advisory boards and lecture fees

GlaxoSmithKline Yes Advisory boards and lecture fees

Novartis Yes Advisory boards and lecture fees

Sanofi Yes Advisory boards

Teva Yes Advisory boards and lecture fees

Boehringer-Ingelheim Yes Advisory boards and lecture fees

GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST Name: Alvaro A. Cruz

Member of: GINA Board of Directors Are there any relevant financial interests to disclose?



GSK X* X *Investigator

initiated AstraZeneca X X X Boehringer-Ingelheim X X CHIESI X Merk, Sharp & Dohme X

DISCLOSURE OF FINANCIAL INTEREST Name: Mark FitzGerald, MD

Member of: GINA Board of Directors, GINA Science Committee Are there any relevant financial interests to disclose? Yes; see below

1. PERSONAL BENEFITS* Includes fees (for lectures, advisory committees, travel grants, or consultancy services) either intermittent or regular, from which you benefit personally.

Company < $10,000 > $10,000 Nature/Purpose of Payment

BI GSK AZ Novartis Teva Merck

X X X X X

X

Advisory board Consulting for study design Lectures, advisory board, Advisory board and lecture fees Advisory board Lecture fees

* Check category only; do not list the amount received.

2. SHARES* Includes shares in the asthma related pharmaceutical/medical device industry, excluding pension plans, mutual funds or unit trusts, held by a GINA member or family members (spouse and children < 18 years).

Company < $10,000 > $10,000

None

*Check category only; do not list the number of shares or $ amount. 3. NON-PERSONAL INTERESTS* Includes fees or grants paid to a GINA member and used for research, education, equipment, salaries, etc.

Company < $10,000 > $10,000 Nature/Purpose of Support

AZ GSK Merck Novartis Sanofi

X Research funds paid directly to UBC for all companies and all greater than $10,000

* Check category only; do not list amount of funding received.

I confirm that these forms are complete. Name: _______________________ (Choose one or both) ____GINA Board of Directors _____ GINA Science Committee

Signature: Date:

GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST Name: Hiromasa Inoue

Member of: GINA Board of Directors, GINA Science Committee Are there any relevant financial interests to disclose?



Nippon Boehringer Ingelheim X X Chugai Pharmaceutical X X Kyorin Pharmaceutical X X Novartis Pharma X X Ono Pharmaceutical X X MSD X Teijin Pharma X Pfizer Japan X Taiho Pharmaceutical X Mitsubishi Tanabe Pharma X AstraZeneca X GlaxoSmithKline X Sanofi X Sumitomo Dainippon Pharma X

GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST Name: Jiangtao Lin

Member of: GINA Board of Directors Are there any relevant financial interests to disclose? No



GLOBAL INITIATIVE FOR ASTHMA (GINA)

DISCLOSURE OF FINANCIAL INTEREST Name: Søren Pedersen

Member of: GINA Board of Directors, GINA Science Committee Are there any relevant financial interests to disclose?



AstraZeneca + Lectures ALK + Advisory board Thermofisher + Advisory board


DISCLOSURE OF FINANCIAL INTEREST Name: Helen Reddel

Member of: GINA Board of Directors, GINA Science Committee Are there any relevant financial interests to disclose? Yes



AstraZeneca Yes Yes Yes No Advisory boards, steering committee, DSMB, independent medical education, medical writing support

Boehringer Ingelheim No Yes No No Independent medical education

GlaxoSmithKline Yes Yes No No DSMB Merck No Yes No No DSMB Novartis No Yes No No DSMB, advisory

board


DISCLOSURE OF FINANCIAL INTEREST Name: Arzu Yorgancıoglu

Member of: GINA Board of Directors and D&I Committee Are there any relevant financial interests to disclose?



Astra Zeneca yes yes yes

Advisory board, Invited speaker grant to institution

GlaxoSmithKline no no yes Advisory board, Invited speaker

Novartis no yes yes

Advisory board, Invited speaker grant to institution

Boehringer Ingelheim no yes yes Invites speaker Sanofi no yes yes Advisory Board ALK no yes yes Advisory Board

MSD yes no no grant to institution

Chiesi no yes yes Advisory board, Invited speaker

Global Alliance against Chronic Respiratory Diseases (GARD)/WHO

no no yes

Support for travel to meetings Vice Chair

Turkish Thoracic Society no no yes

Support for travel to meetings GARD Turkey Coordinator


DISCLOSURE OF FINANCIAL INTEREST Name: Leonard B Bacharier, MD

Member of: GINA Science Committee Are there any relevant financial interests to disclose? Yes



Teva X Advisory board

GlaxoSmithKline X Advisory board, speaker bureau

Novartis X Honoraria for lectures

AstraZeneca X

Honoraria for lectures, Advisory Board

DBV Technologies X DSMB Member

Sanofi X Honoraria for lectures

Regeneron X Honoraria for lectures

BoehringerIngelheim X

Development of educational materials

Vectura X Consultant fees


DISCLOSURE OF FINANCIAL INTEREST Name: Dr. Louise Fleming




Novartis

Attendance at standalone advisory boards and payment for lectures; all fees paid to institution

GSK

Attendance at standalone advisory boards; all fees paid to institution

Boehringer Ingelheim

Attendance at standalone advisory boards and payment for lectures; all fees paid to institution

Teva

Payment for lecture; all fees paid to institution

Astra Zeneca

Payment for lecture; all fees paid to institution

Sanofi


Respiri UK



DISCLOSURE OF FINANCIAL INTEREST Name: Jerry Krishnan

Member of: GINA Science Committee Are there any relevant financial interests to disclose?



National Institutes of Health Patient Centered Outcomes Research Institute

Sanofi

X (Independent Data Monitoring Committee)

Vanguard mutual funds


DISCLOSURE OF FINANCIAL INTEREST Name: Aziz Sheikh

Director of: Scottish Allergy and Respiratory Academy (SARA) and Asthma UK Centre for Applied Research Are there any relevant financial interests to disclose? Yes



Mylan Yes

Sponsorship for Scottish Allergy & Respiratory Academy (SARA) – a not-for-profilt training programme for healthcare professionals

Nutricia Yes Sponsorship for SARA

GSK Yes Sponsorship for SARA

Napp Yes Sponsorship for SARA

Mead Johnson Ltd Yes Sponsorship for SARA

Chiesi Yes Sponsorship for SARA

Bausch & Lomb Yes Sponsorship for SARA

GSK Yes

Travel support to attend scientific meeting

GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST Name: Fanny Wai San KO




Boehringer Ingelheim (HK) Ltd. through CHEST Delegation Hong Kong and Macau limited: Support for attending the ERS 2018 conference

Attending conference

September 2018

Astra Zenaca through Hong Kong Thoracic Society: Support for attending the ATS 2018 conference

Attending conference

May 2018

2018 disclosure of interest information · soren erik pedersen, md - chair helen k. reddel, mbbs,...

Documents